We expect that ANA975 will provide the same combination of anti-viral effect and tolerability as observed with isatoribine, but with the added advantage of oral administration, said Steve Worland, PhD, Anadys executive vice president of research and development. The pharmaceutical properties of ANA975 along with the preclinical data further support our belief that ANA975 provides the potential to become an orally administered frontline treatment for chronic hepatitis C virus (HCV) infection.
The Phase I clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of ANA975 in healthy volunteers. The study is an open-label, ascending single-dose evaluation of ANA975 to be administered orally to a total of 18 subjects in three cohorts at 400 mg, 800 mg and 1200 mg doses. The trial is being conducted in the
ANA975 is an oral prodrug of Anadys proprietary compound isatoribine. To date, isatoribine has been administered to 64 subjects, including 44 patients chronically infected with hepatitis C. Data from the Phase IB clinical trial of isatoribine, presented at the American Association for the Study of Liver Diseases (AASLD) 2004 Annual Meeting in
We are very pleased to introduce ANA975 into the clinic ahead of schedule, said Kleanthis G. Xanthopoulos, PhD, Anadys president and CEO. We are using our expertise in Toll-Like Receptor-based biology and chemistry to build a strong portfolio of product candidates. We believe that we are at the forefront of this effort and have expanded our position around small molecules targeting Toll-Like Receptors.
Source: Anadys Pharmaceuticals, Inc.